Table 1 Reduction of clinical parameters by liposomal dexamethasone phosphate on Days 19 and 28 of adjuvant arthritis
Experiment 1 | Arthritis score | Paw volume | ||
|---|---|---|---|---|
   Treatment | Day 19 | Day 28 | Day 19 | Day 28 |
   AA/PBS | -- | -- | -- | -- |
   AA/PBS-liposomes | +23% ± 29.4% | +36% ± 56.5% | + 2% ± 38.8% | +47% ± 62.3% |
   AA/DxM-P | -51% ± 17.8% | + 4% ± 41.7% | -65% ± 14.0% | -13% ± 26.4% |
   AA/liposomal DxM-P | -95% ± 3.2%++ ## | -54% ± 28.7% | -92% ± 7.4%++ # | -73% ± 17.3% + |
Experiment 2/3 | Arthritis score | Paw volume | ||
   Treatment | Day 19 | Day 29* | Day 19 | Day 29* |
   AA/PBS | -- | -- | -- | -- |
   AA/PBS-liposomes | +15% ± 19.8% |  | +23% ± 20.3% |  |
   AA/DxM-P | -67% ± 16.4% + # |  | -52% ± 21.8% + # |  |
   AA/liposomal DxM-P | -90% ± 5.0%++ ## |  | -87% ± 6.6.%++ ## |  |
   AA/liposomal DxM-P 1Ă— * | -48% ± 23.9% | -15% ± 29.6% | -63% ± 24.6% | -35% ± 22.6% |